1. At a Glance
Religare Enterprises Ltd (REL) is the perfect desi comeback story—part financial services, part courtroom drama, and part redemption arc. Once a cautionary tale starring the Singh brothers and ₹2,500 crore “misplaced” funds, it now flaunts a market cap of ₹8,472 crore, a 3-month return of 2.57%, and a current price of ₹256 as of November 21, 2025.
The company today straddles three pillars: Health Insurance (74.5% of revenue) through Care Health Insurance Ltd (CHIL), Lending (15%) through Religare Finvest Ltd (RFL) and RHDFCL, and Retail Broking (8.5%) via Religare Broking Ltd.
But the real masala?
REL just raised ₹1,500 crore through a preferential issue of warrants at ₹235 each in September 2025, with promoters contributing 50%. That’s right—the company that once begged RBI to revive its subsidiaries is now throwing cash at them.
Quarterly sales jumped to ₹2,064 crore, but PAT slipped 24% QoQ to ₹38.8 crore. Despite a humble 5.15% ROE, the crowd still loves a good comeback story—and Religare’s got that under its shiny CFO reshuffle.
2. Introduction – The Once and Future Banker
Remember when “Religare” used to mean “religiously investing in trouble”? Those days are almost gone. The company that once watched its promoters—Shivinder and Malvinder Singh—transform “corporate governance” into a Netflix crime series has quietly been reborn.
From being barred by RBI in 2018 under a Corrective Action Plan to repaying ₹6,500 crore in dues, REL’s turnaround is practically MBA case-study material. The ghost of Religare Finvest’s fraud tag was finally exorcised in August 2025, when the Delhi High Court ordered banks to remove the “fraud” classification.
Now, under the leadership of Chairperson Rashmi Saluja (and a new CFO, Pratul Gupta, appointed November 2025), the company has moved from courtroom hearings to earnings calls.
REL’s subsidiaries—CHIL, RFL, and RHDFCL—cover India’s financial needs like a buffet: loans for the small guy, insurance for the unlucky guy, and broking for the brave guy.
So what’s changed? A clean-up act that’s turned this scandal-scarred house into a disciplined financial fortress (well, sort of). But as every investor knows—when a financial company has a history this spicy, due diligence is not optional—it’s entertainment.
3. Business Model – WTF Do They Even Do?
Let’s decode the Religare recipe:
A) Lending (15% revenue share)
Religare Finvest Ltd (RFL) and Religare Housing Development Finance Corp Ltd (RHDFCL) handle SME finance and affordable housing loans. Once on RBI’s naughty list, these entities are back to lending selectively, still recovering from the ₹2,500 crore saga. The loan book once stood at ₹2,452 crore, and though the growth isn’t gangbusters, the quality’s definitely cleaner.
B) Health Insurance (74.5%)
Care Health Insurance Ltd (CHIL) is Religare’s crown jewel. With a gross written premium (GWP) exceeding ₹2,400 crore in FY20, it’s the segment keeping the group alive. CHIL raised ₹300 crore from Kedaara Capital and Trishikhar Ventures, signaling that serious money is betting on this recovery.
C) Retail Broking (8.5%)
Religare Broking Ltd covers everything from equities to commodities to PMS.
